2023
DOI: 10.1111/ddg.15020
|View full text |Cite
|
Sign up to set email alerts
|

New therapeutic developments for basal cell carcinoma

Abstract: SummaryIn 2013, systemic therapy was introduced into the treatment of locally advanced (laBCC) and metastatic basal cell carcinoma (mBCC). Meanwhile, immunotherapy has been approved in this indication as well. Additional immunotherapies and other classes of drugs including combination regimens are currently being investigated in clinical trials. These agents might considerably expand the therapeutic armamentarium for laBCC and mBCC in the future.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 26 publications
0
1
0
Order By: Relevance
“…31 In such cases with extensive cartilage involvement, systemic treatment options such as HHIs or PD1-inhibitors may offer a neoadjuvant approach, shrinking the tumor and thus avoiding significant functional impairment by decreasing the dimensions of the consecutive resection defects. [32][33][34] For tumors with localized cartilage involvement identified in the pre-surgical setting using HFUS, the number of surgical steps can be reduced, as surgeons can immediately resect the tumor mass including the cartilaginous tumor infiltration, sparing operating time and perioperative anxi-ety in often very frail patients and enabling a quicker tumor resection and reconstruction.…”
Section: Discussionmentioning
confidence: 99%
“…31 In such cases with extensive cartilage involvement, systemic treatment options such as HHIs or PD1-inhibitors may offer a neoadjuvant approach, shrinking the tumor and thus avoiding significant functional impairment by decreasing the dimensions of the consecutive resection defects. [32][33][34] For tumors with localized cartilage involvement identified in the pre-surgical setting using HFUS, the number of surgical steps can be reduced, as surgeons can immediately resect the tumor mass including the cartilaginous tumor infiltration, sparing operating time and perioperative anxi-ety in often very frail patients and enabling a quicker tumor resection and reconstruction.…”
Section: Discussionmentioning
confidence: 99%